Pelubiprofen

Summary

Pelubiprofen (CHEMBL69308) is a phase-3 clinical-stage small molecule (ATC M01AE20); indicated across 5 conditions including rheumatoid arthritis and rheumatic disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: M01AE20
• Indications: 5 conditions
• Clinical trials: 6
• Chemistry: 258.31 Da · C16H18O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL69308
Name	Pelubiprofen
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5282203
ATC	M01AE20
Molecular formula	C16H18O3
Molecular weight	258.31
InChIKey	AUZUGWXLBGZUPP-GXDHUFHOSA-N

SMILES: CC(C1=CC=C(C=C1)/C=C/2\CCCCC2=O)C(=O)O

IUPAC name: 2-[4-[(E)-(2-oxocyclohexylidene)methyl]phenyl]propanoic acid

Also known as: CS-670, Pelubiprofen, Pelubiprofene, Pelubiprofeno, RS-2131, SID124894216, SID144206823, PELUBIPROFEN

Patent coverage: 197 distinct patent families (860 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatoid arthritis	3	MONDO:0008383	EFO:0000685
rheumatic disorder	3	MONDO:0005554	EFO:0005755

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE3	5
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01779271	PHASE3	COMPLETED	Phase 3 Study of Pelubiprofen & Loxoprofen in Patients With Upper Respiratory Tract Infection
NCT01781702	PHASE3	COMPLETED	Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients
NCT02375633	PHASE3	COMPLETED	Phase 3 Study of DW-330SR2 and Pelubiprofen in Chronic Back Pain Patients
NCT03874247	PHASE3	UNKNOWN	Clinical Trial to Evaluate the Efficacy and Safety of ‘Pelubiprofen Controlled Released Tab.’ in Acute Traumatic Injury
NCT04541134	PHASE3	UNKNOWN	Phase 3 Clinical Trial to Evaluate of the Efficacy and Safety of DW9801 in Patients With Primary Dysmenorrhea
NCT01776697	PHASE1	COMPLETED	Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR TID and Pelubiprofen SR (as a Pelubiprofen 90 mg) Tablet QD in Healthy Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).